drugset / Trial / NCT00547261
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-08
- Completion
- 2008-08
Outcome
Outcome not reported
Stopped: “Due to lack of supply of the investigational product.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SSR97225 | Unknown | — | Intravenous |